• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alphatec Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    5/5/26 4:28:52 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    8-K
    false000135065300013506532026-05-012026-05-01

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 01, 2026

     

     

    Alphatec Holdings, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-52024

    20-2463898

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1950 Camino Vida Roble

     

    Carlsbad, California

     

    92008

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 760 431-9286

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $.0001 per share

     

    ATEC

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 1, 2026 (the “Closing Date”), Alphatec Holdings, Inc. (the “Company”) and certain of its domestic subsidiaries (collectively, the “Subsidiary Guarantors”), as guarantors party thereto, entered into a senior secured credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”) and the lenders and issuing banks party thereto. The Credit Agreement provides for (i) a $175.0 million term loan A facility (the “Term Loan A”) and (ii) a $125.0 million revolving credit facility, with a sublimit of up to $20.0 million for foreign currency loans, $30.0 million for the issuance of letters of credit and $10.0 million for swingline loans(the “Revolving Credit Facility” and, together with the Term Loan A, the “Credit Facilities”). The Credit Facilities mature on the fifth anniversary of the Closing Date (the “Scheduled Maturity Date”), subject to a springing maturity during the period from (a) December 14, 2029 (the date that is 91 days prior to the scheduled maturity date of the Company’s existing 0.75% convertible senior notes due 2030 (the “2030 Convertible Notes”)) until (b) the earlier of (i) March 15, 2030 (the scheduled maturity date of the 2030 Convertible Notes or the later scheduled maturity date of any extension or refinancing of the 2030 Convertible Notes that has a scheduled maturity date prior to the 91st day of the Scheduled Maturity Date) and (ii) the date on which the outstanding principal amount of the 2030 Convertible Notes and any extension or refinancing thereof is less than or equal to $85.0 million, if the Company and its subsidiaries fail to maintain liquidity (defined as unrestricted cash held in the U.S. plus amounts available under the Revolving Credit Facility) in an amount equal to or greater than the sum of (x) the outstanding principal amount of the 2030 Convertible Notes and any extension or refinancing thereof plus (y) $100.0 million.

     

    The loans under the Revolving Credit Facility may be denominated in U.S. dollars, Euros, Sterling, Australian Dollars, Singapore Dollars, Swiss Francs, and Japanese Yen. Loans borrowed under the Term Loan A may only be denominated in U.S. dollars. Loans incurred under the Credit Facilities bear interest at a rate equal to, (i) for loans denominated in U.S. dollars, at the Company’s election, Term SOFR Rate or the Alternate Base Rate (each as defined in the Credit Agreement) and (ii) for loans denominated in foreign currencies, the applicable Relevant Rate (as defined in the Credit Agreement), in the case of each of the foregoing clauses (i) and (ii), plus an applicable margin based on the Company’s Senior Secured Net Leverage Ratio (defined as total indebtedness of the Company and its subsidiaries that is secured by a lien on the assets of the Company and its subsidiaries, minus any unrestricted cash of the Company and its subsidiaries in excess of $100.0 million to Consolidated EBITDA (as defined in the Credit Agreement). The applicable margin ranges from 1.00% to 2.50% for ABR Loans and 2.00% to 3.50% for Term Benchmark Loans and RFR Loans (each as defined in the Credit Agreement).

     

    The Credit Agreement provides for (i) quarterly amortization payments on the Term Loan A equal to, for the first eight full fiscal quarters after the Closing Date, 0.625% of the aggregate principal amount of the Term Loan A advanced on the Closing Date, stepping up to 1.25% for the ninth through sixteenth full fiscal quarters after the Closing Date, and for each fiscal quarter thereafter, 2.50%, with the remaining balance due at maturity, (ii) commitment fees on the unused commitments under the Revolving Credit Facility, ranging from 0.20% to 0.35% per annum based on the Company’s Senior Secured Net Leverage Ratio, and (iii) an incremental accordion feature of up to the sum of (x) the greater of (A) $150.0 million and (B) 100% of Consolidated EBITDA of the Company, plus (y) the amount of any voluntary prepayments of the Term Loan A and voluntary permanent reductions of the commitments under the Revolving Credit Facility, subject to customary conditions.

     

    On the Closing Date, the Company borrowed $175.0 million of the Term Loan A, and $40.0 million of loans under the Revolving Credit Facility. Proceeds from the Credit Facilities were used, together with the Company’s cash on hand, (a) to repay in full all outstanding obligations under that certain (i) Credit, Security and Guaranty Agreement, dated as of September 29, 2022 (as amended, restated, supplemented or otherwise modified prior to the Closing Date), among the Company, the other borrowers from time to time party thereto, the lenders party thereto and MidCap Funding IV Trust, as the administrative agent (the “ABL Credit Agreement”) and (ii) Credit, Security and Guaranty Agreement, dated as of January 6, 2023 (as amended, restated, supplemented or otherwise modified prior to the Closing Date), among the Company, the guarantors from time to time party thereto and Wilmington Trust, National Association, as agent (the “2023 Term Loan Agreement,” and together with the ABL Credit Agreement, the “Prior Credit Agreements”) and (b) to pay certain costs, fees and expenses in connection with the transaction on the Closing Date.

     

    The Credit Agreement requires the Company to maintain (i) a Senior Secured Net Leverage Ratio not exceeding 3.00 to 1.00, subject to, at the Company’s election, a step-up to 3.50 to 1.00 following the completion of certain permitted acquisitions having consideration that is equal to or greater than $75.0 million, and (ii) a Fixed Charge Coverage Ratio (defined as Consolidated EBITDA minus unfinanced capital expenditures to consolidated fixed charges) of at least 2.00 to 1.00, in each case tested quarterly commencing with the fiscal quarter ending September 30, 2026.

    The Credit Facilities are guaranteed by the Subsidiary Guarantors and secured by substantially all of the assets of the Company and the Subsidiary Guarantors, subject to customary exclusions and limitations set forth in the Credit Agreement and the related loan documents. The Credit Agreement contains representations and warranties and affirmative and negative covenants that are usual and customary, including negative covenants that, subject to the exceptions set forth in the Credit Agreement, limit the ability for the Company and its subsidiaries to incur additional debt, incur or permit liens on assets, make investments and acquisitions, consolidate or merge with any other company, engage in asset sales and make dividends and distributions.

     


    Obligations under the Credit Agreement may be accelerated upon the occurrence of certain customary events of default (subject, in appropriate cases, to grace periods set forth in the Credit Agreement), including among others: nonpayment of principal, interest or fees; breach of the affirmative, negative or financial covenants; breach of the representations or warranties in any material respect; events of default with respect to other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries that are not promptly paid or stayed; invalidity or unenforceability of the security documents and guarantees associated with the Credit Agreement; and a change of control of the Company.

     

    On May 5, 2026, the Company issued a press release announcing the Credit Agreement. A copy of the press release is attached hereto as Exhibit 99.1.

    The foregoing description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 1.02 Termination of a Material Definitive Agreement.

     

    On May 1, 2026, in connection with the entry into the Credit Agreement, the Company terminated the Prior Credit Agreements. On such date, the Company repaid in full all outstanding principal, accrued interest and applicable fees under each of the Prior Credit Agreements. The disclosure set forth in Item 1.01 above with respect to the Prior Credit Agreements is incorporated by reference into this Item 1.02.

     

    A description of the ABL Credit Agreement is included in Item 1.01 of the Current Report on Form 8-K filed by the Company on October 3, 2022 and is incorporated by reference into this Item 1.02. A description of the 2023 Term Loan Agreement is included in Item 1.01 of the Current Report on Form 8-K filed by the Company on January 9, 2023 and is incorporated by reference into this Item 1.02.

     

    Item 2.02 Results of Operations and Financial Condition.

     

    The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition,” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

     

    On May 5, 2026, the Company issued a press release announcing its financial results for its period ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.2.

     

    The information contained in this Current Report, including the exhibit, shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    10.1

    Form of Confirmation of Credit Agreement dated May 1, 2026

    99.1

    Press Release of Alphatec Holdings, Inc., dated May 5, 2026

    99.2

    Press Release of Alphatec Holdings, Inc., dated May 5, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Alphatec Holdings, Inc.

     

     

     

     

    Date:

    May 5, 2026

    By:

    /s/ J. Todd Koning

     

     

     

    J. Todd Koning
    Executive Vice President and Chief Financial Officer

     


    Get the next $ATEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    10/28/2025$20.00Buy
    Stifel
    10/24/2025$19.00Overweight
    Analyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    More analyst ratings

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Keith bought $996,192 worth of shares (135,000 units at $7.38), increasing direct ownership by 139% to 232,271 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    5/11/26 7:00:05 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:32:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:27:25 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Keith bought $996,192 worth of shares (135,000 units at $7.38), increasing direct ownership by 139% to 232,271 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    5/11/26 7:00:05 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Marshall Tyson Eliot

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    4/9/26 5:42:40 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Koning John Todd sold $986,192 worth of shares (79,789 units at $12.36), decreasing direct ownership by 12% to 600,721 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    3/17/26 5:30:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    SEC Filings

    View All

    SEC Form SD filed by Alphatec Holdings Inc.

    SD - Alphatec Holdings, Inc. (0001350653) (Filer)

    5/28/26 4:52:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Alphatec Holdings Inc.

    10-Q - Alphatec Holdings, Inc. (0001350653) (Filer)

    5/5/26 4:56:19 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Alphatec Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

    5/5/26 4:28:52 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATEC Refinances Existing Debt with Inaugural Bank Facility

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced it has entered into a new credit facility, including a $125 million revolving credit facility and $175 million Term Loan A, led by JPMorgan Chase Bank, N.A. and TD Securities (USA) LLC. This transaction represents ATEC's inaugural syndicated bank facility and reflects the Company's strong operating performance and continued progression to a more scaled and profitable financial profile. The new facility refinances the Company's existing debt, including its prior term loan and asset-based lending facilities with Braidwell LP, Pha

    5/5/26 4:05:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC Reports First Quarter Financial Results

    Surgical revenue grew 17%; total revenue grew 14% Company announces refinancing of existing debt with inaugural bank facility, reducing interest expense by more than $6 million annually and extending maturities to 2031 Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2026, and business highlights. First Quarter 2026 Financial Results Quarter Ended March 31, 2026 Total revenue $192 million GAAP gross margin 71% Non-GAAP gross margin 72% GAAP operating expenses

    5/5/26 4:05:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report First Quarter 2026 Financial Results on May 5, 2026

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2026 financial results on May 5, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Analyst Participation To participate in the question-and-answer session, analysts must register in advance using this link. Upon registration, access details, including a unique code, will be provided via email. Replay A replay of the webcast will remai

    4/23/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Alphatec with a new price target

    Stifel resumed coverage of Alphatec with a rating of Buy and set a new price target of $20.00

    10/28/25 7:09:19 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on Alphatec with a new price target

    Analyst initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

    10/24/25 8:59:42 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Lake Street resumed coverage on Alphatec with a new price target

    Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

    6/16/25 8:53:19 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    View All

    ATEC Mourns Passing of Board Member Jeffrey P. Rydin

    Alphatec Holdings, Inc. (NASDAQ:ATEC) ("ATEC"), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced with great sadness that Jeffrey P. Rydin, a valued member of its Board of Directors, has passed away at age 59, following a lengthy illness. Mr. Rydin enjoyed nearly three decades of experience in the medical device and healthcare industries, including senior sales leadership roles at Ellipse Technologies, Inc., NuVasive, Inc., and DePuy Spine, Inc. He was one of the earliest to join the ATEC turnaround effort, coming to the Company as a Special Advisor to the Board in September 2016, in which capacity he drove many of the early deci

    11/7/25 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    12/11/24 9:00:00 AM ET
    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care

    Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

    Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

    4/4/24 9:05:00 AM ET
    $ATEC
    $SYK
    Medical/Dental Instruments
    Health Care

    $ATEC
    Financials

    Live finance-specific insights

    View All

    ATEC to Report First Quarter 2026 Financial Results on May 5, 2026

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2026 financial results on May 5, 2026, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Analyst Participation To participate in the question-and-answer session, analysts must register in advance using this link. Upon registration, access details, including a unique code, will be provided via email. Replay A replay of the webcast will remai

    4/23/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook

    Full-year 2025 total revenue grew 25% to approximately $764 million Expect full-year 2026 total revenue of $890 million Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31, 2025. The Company also provided a financial outlook for full-year 2026. Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Select Financial Results   Fourth Quarter Ended December 31, 2025 Full Year Ended December 31, 2025 Surgical Revenue $189.3M to $190.0M $686.3M to

    1/12/26 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report Third Quarter 2025 Financial Results on October 30, 2025

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2025 financial results on October 30, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations section of ATEC's corporate website. Dial-In To dial into the live webcast, please register at this link. Access details will be provided via email. Replay A replay of the webcast will remain available through the Investor Relations section of ATEC's corporate website for twelve month

    10/16/25 4:10:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    11/12/24 8:04:57 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    3/22/24 7:57:56 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    5/12/23 4:51:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care